Aldavar, a Korean startup developing next-generation medical simulators using biopolymer new material technology, has successfully raised 11 billion won ($7.7 million) in Series A funding. The funding round saw participation from new investors SL Investment, Korea Investment Partners, and Daily Partners, while existing backers KB Investment and Ascendo Ventures continued their support with follow-on investments.
Aldavar specializes in creating medical devices and training simulators by synthesizing biopolymer materials and leveraging advanced 3D printing technologies. Its flagship artificial organs have received significant acclaim from medical professionals for their ability to replicate the mechanical and electrical properties of real human organs. These innovations have already undergone rigorous testing with global medical device companies at 10 training centers across six countries, demonstrating their capability to replace traditional training tools like pig organs.
Rising Demand for Ethical and Sustainable Simulators
As the development of advanced medical technologies, such as surgical robots, accelerates, the demand for ethical and sustainable bio-simulators has surged. Traditional methods involving pigs and cadavers face mounting ethical and legal challenges, creating a pressing need for alternatives. Aldavar’s biopolymer-based simulators provide a sustainable and effective solution to this growing demand.
The newly secured funds will be channeled into expanding Aldavar’s simulator offerings from urology to laparoscopic surgery, enhancing its global market penetration, and recruiting top-tier international marketing talent.
Plans for Expansion and Innovation
Kim Jin-oh, Co-CEO of Aldavar, shared the company’s vision: “With this investment, we plan to fully operationalize our artificial organ manufacturing facility in the Osong Advanced Medical Complex, which was completed this October. This will enable us to ensure product quality and commence large-scale production for global medical device companies next year. In the long term, we aim to become a global leader in medical simulation by expanding our portfolio to include simulators for all human organs and advancing new material development.”
A Future of High Potential
An investment reviewer emphasized Aldavar’s unique value proposition, stating: “With their deep expertise in biopolymers and cutting-edge technology, Aldavar provides a hyper-realistic surgical simulation environment. Their focus on replicating blood flow dynamics and micromuscle movements positions them for exceptional growth in the global market.”
Aldavar has been a standout in the innovation ecosystem. It is a graduate of the third cohort of the ‘IBK Changgong’ program by IBK Industrial Bank of Korea and has won accolades such as the 2023 Challenge! K-Startup Grand Prize. It was also selected as a 2024 Baby Unicorn fostering company, solidifying its position as a key player in the medical technology landscape.
Keep tab on latest news in the Korean startup ecosystem & follow us on LinkedIN, Facebook, and Twitter for more exciting updates and insights.
